INOVIQ LTD. Net Assets
INOVIQ LTD. net assets. Based on the latest financial reports, INOVIQ LTD. (EGQ0) has net assets worth €19.99 Million EUR (≈ $23.37 Million USD) as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€21.71 Million ≈ $25.38 Million USD) and total liabilities (€1.72 Million ≈ $2.01 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of INOVIQ LTD. to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €19.99 Million |
| % of Total Assets | 92.08% |
| Annual Growth Rate | -22.66% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 16.34 |
Net Assets of INOVIQ LTD. (2021–2024)
Net assets of INOVIQ LTD. from 2021 to 2024. This chart illustrates how INOVIQ LTD.'s net assets have evolved over time, based on quarterly financial data. See net asset quality index of INOVIQ LTD. to measure how much of total assets are equity-financed.
Annual Net Assets for INOVIQ LTD. (2021–2024)
The table below shows the annual net assets of INOVIQ LTD. from 2021 to 2024. For live market cap and overall valuation, see EGQ0 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | €19.99 Million ≈ $23.37 Million |
+1.89% |
| 2023-06-30 | €19.62 Million ≈ $22.93 Million |
-30.67% |
| 2022-06-30 | €28.29 Million ≈ $33.08 Million |
-34.53% |
| 2021-06-30 | €43.22 Million ≈ $50.53 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to INOVIQ LTD.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3174465800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
INOVIQ LTD. Net Assets Breakdown (June 2024)
INOVIQ LTD. net assets breakdown by equity component as of June 2024.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €76.90 Million | 384.77% |
| Total Equity | €19.99 Million | 100.00% |
INOVIQ LTD. Competitors by Market Cap
The table below lists competitors of INOVIQ LTD. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nexgram Holdings Bhd
KLSE:0096
|
$13.50 Million |
|
StarFlex Co. Ltd
KQ:115570
|
$13.50 Million |
|
ZOONO Group Ltd
AU:ZNO
|
$13.51 Million |
|
Khind Holdings Bhd
KLSE:7062
|
$13.51 Million |
|
Purepoint Uranium Group Inc
V:PTU
|
$13.49 Million |
|
Xinyuan Real Estate Co Ltd
NYSE:XIN
|
$13.49 Million |
|
Lena Lighting S.A.
WAR:LEN
|
$13.49 Million |
|
Geratherm Medical AG
XETRA:GME
|
$13.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INOVIQ LTD.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,615,397 to 19,986,328, a change of 370,931 (1.9%).
- Net loss of 6,554,350 reduced equity.
- Share repurchases of 508,535 reduced equity.
- New share issuances of 6,750,000 increased equity.
- Other factors increased equity by 683,816.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-6.55 Million | -32.79% |
| Share Repurchases | €508.54K | -2.54% |
| Share Issuances | €6.75 Million | +33.77% |
| Other Changes | €683.82K | +3.42% |
| Total Change | €- | 1.89% |
Book Value vs Market Value Analysis
This analysis compares INOVIQ LTD.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.43x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.24x to 0.43x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | €0.35 | €0.08 | x |
| 2022-06-30 | €0.31 | €0.08 | x |
| 2023-06-30 | €0.21 | €0.08 | x |
| 2024-06-30 | €0.19 | €0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INOVIQ LTD. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1224.84%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.09x
- Recent ROE (-32.79%) is above the historical average (-46.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -44.42% | -2642.00% | 0.01x | 1.74x | €-15.15 Million |
| 2022 | -64.31% | -6575.00% | 0.01x | 1.09x | €-21.03 Million |
| 2023 | -45.73% | -2252.49% | 0.02x | 1.10x | €-10.93 Million |
| 2024 | -32.79% | -1224.84% | 0.02x | 1.09x | €-8.55 Million |
Industry Comparison
This section compares INOVIQ LTD.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,811,646,934
- Average return on equity (ROE) among peers: -37.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INOVIQ LTD. (EGQ0) | €19.99 Million | -44.42% | 0.09x | $13.50 Million |
| IZOTROPIC CORP. (1R3) | $-3.85 Million | 0.00% | 0.00x | $6.11 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $4.18 Million | -188.49% | 2.68x | $839.64K |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $24.45 Billion | 8.28% | 0.21x | $604.57 Million |
| Check-Cap Ltd (7CC) | $16.38 Million | -84.54% | 0.20x | $9.20 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $3.50 Billion | 30.79% | 1.04x | $251.46 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $32.00 Million | -74.44% | 0.67x | $2.36 Million |
| GENINCODE PLC LS -01 (9PL) | $7.90 Million | -70.37% | 0.49x | $5.28 Million |
| Eurofins Scientific SE (ESF0) | $4.68 Billion | 16.73% | 1.00x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $1.62 Billion | 23.11% | 0.80x | $7.52 Billion |
About INOVIQ LTD.
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non… Read more